ACVR2A and pulmonary arterial hypertension: Sotatercept, a fusion protein comprising the extracellular ligand binding domain of ActRIIA fused to the Immunoglobin Fc domain, is approved by the FDA for treating Group 1 PAH and is the first PAH therapy targeting the TGF-β superfamily.